Clinical Trial Detail

NCT ID NCT01974258
Title Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche

lung non-small cell carcinoma


Advanced Solid Tumor

colorectal cancer


Onartuzumab + Vemurafenib

Cobimetinib + Onartuzumab

Cobimetinib + Onartuzumab + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST